---
title: SCLC staging and treatment
---
# SCLC staging and treatment

* SCLC usually disseminated at presentation; poor overall survival
* Can be very responsive to chemotherapy, but rapidly develop resistance
* Diagnosis: all have Rb & p53 mutations (Nature 2015;524:47); 90% w/ neuroendo markers
* Treatment: primarily chemo (platinum + etoposide); adding anti-[[PD-L1]] Ab [[atezolizumab]]
â†‘ survival (NEJM 2018;379:2220), as does concurrent thoracic RT in limited-stage disease
![SCLC Staging Schema and Treatment](https://i.imgur.com/KhoAVhU.png)
* Prophylactic cranial irradiation (PCI) controversial. Offered to potentially â†‘ survival for LS-SCLC in complete remission (NEJM 1999;341:476). Role in ES-SCLC being studied.
* Second line: low response rates, short survival. Options: lurbinectedin, single-agent chemo (eg, topotecan, docetaxel), reRx w/ platinum doublet, anti-PD-1 (eg, nivo).


## Explain by ChatGPT


- **SCLC staging and treatment**: 
  - **SCLC usually disseminated at presentation**; **poor overall survival**
  - Can be very responsive to chemotherapy, but rapidly develop resistance
  - Diagnosis: all have Rb & p53 mutations; 90% w/ neuroendo markers
  - Treatment: primarily chemo (platinum + etoposide); adding anti-[[PD-L1]] Ab [[atezolizumab]]
â†‘ survival, as does concurrent thoracic RT in limited-stage disease
  - [[Prophylactic cranial irradiation]] (PCI) controversial. Offered to potentially â†‘ survival for LS-SCLC in complete remission. Role in ES-SCLC being studied.
  - Second line: low response rates, short survival. Options: lurbinectedin, single-agent chemo (eg, topotecan, docetaxel), reRx w/ platinum doublet, anti-PD-1 (eg, nivo).

## çª©çš„è‹±æ–‡ä¸å¤ªå¥½ï¼Œåªå¥½è«‹ä¼°ğŸ¶

- **SCLC åˆ†æœŸå’Œæ²»ç™‚**ï¼š
  - **SCLC é€šå¸¸åœ¨ä»‹ç´¹æ™‚å‚³æ’­**ï¼› **ç¸½é«”ç”Ÿå­˜ç‡ä½**
  - å°åŒ–ç™‚éå¸¸æ•æ„Ÿï¼Œä½†æœƒè¿…é€Ÿç”¢ç”Ÿè€è—¥æ€§
  - è¨ºæ–·ï¼šå‡æœ‰Rb & p53çªè®Šï¼› 90% w/ neuroendo æ¨™è¨˜
  - æ²»ç™‚ï¼šä¸»è¦æ˜¯åŒ–ç™‚ï¼ˆé‰‘ + ä¾æ‰˜æ³Šè‹·ï¼‰ï¼›æ·»åŠ æŠ— [[PD-L1]] æŠ—é«” [[atezolizumab]]
â†‘ ç”Ÿå­˜æœŸï¼Œèˆ‡å±€é™æœŸç–¾ç—…çš„åŒæ­¥èƒ¸éƒ¨æ”¾ç™‚ä¸€æ¨£
  - é é˜²æ€§é¡±è…¦ç…§å°„ï¼ˆPCIï¼‰æœ‰çˆ­è­°ã€‚æä¾› LS-SCLC å®Œå…¨ç·©è§£çš„æ½›åœ¨ â†‘ ç”Ÿå­˜ã€‚åœ¨ ES-SCLC ä¸­çš„ä½œç”¨æ­£åœ¨ç ”ç©¶ä¸­ã€‚
  - äºŒç·šï¼šåæ‡‰ç‡ä½ï¼Œç”Ÿå­˜æœŸçŸ­ã€‚é¸é …ï¼šlurbinectedinã€å–®è—¥åŒ–ç™‚ï¼ˆä¾‹å¦‚æ‰˜æ³Šæ›¿åº·ã€å¤šè¥¿ç´«æ‰é†‡ï¼‰ã€reRx w/é‰‘é›™è—¥ã€æŠ— PD-1ï¼ˆä¾‹å¦‚ nivoï¼‰ã€‚
